Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs. The company's commercial products include Keveyis, an oral carbonic anhydrase inhibitor for treating hyperkalemic, hypokalemic, and related variants of primary periodic paralysis in the United States; and Macrilen, an oral growth hormone secretagogue receptor agonist for use in the diagnosis of patients with adult growth hormone deficiency in the United States and Canada. Its clinical-stage product candidates are Recorlev, a cortisol synthesis inhibitor, which is in a Phase III clinical trial that is used for the treatment of endogenous Cushing's syndrome; and Veldoreotide, a somatostatin analog that is used for treatment of acromegaly. The company was formerly known as Cortendo plc and changed its name to Strongbridge Biopharma plc in September 2015. Strongbridge Biopharma plc was founded in 1996 and is headquartered in Trevose, Pennsylvania.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone610-254-9200
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$18.03 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date5/9/2019 (Estimated)
OptionableOptionable
Strongbridge Biopharma (NASDAQ:SBBP) Frequently Asked Questions
What is Strongbridge Biopharma's stock symbol?
Strongbridge Biopharma trades on the NASDAQ under the ticker symbol "SBBP."
How were Strongbridge Biopharma's earnings last quarter?
Strongbridge Biopharma plc (NASDAQ:SBBP) issued its quarterly earnings data on Tuesday, February, 26th. The biotechnology company reported $1.64 earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.50) by $2.14. The biotechnology company had revenue of $4.51 million for the quarter, compared to analyst estimates of $5.03 million. Strongbridge Biopharma had a return on equity of 108.51% and a net margin of 176.69%. View Strongbridge Biopharma's Earnings History.
When is Strongbridge Biopharma's next earnings date?
What price target have analysts set for SBBP?
6 brokerages have issued 12 month target prices for Strongbridge Biopharma's shares. Their forecasts range from $11.00 to $18.00. On average, they anticipate Strongbridge Biopharma's share price to reach $14.6667 in the next year. This suggests a possible upside of 225.9% from the stock's current price. View Analyst Price Targets for Strongbridge Biopharma.
What is the consensus analysts' recommendation for Strongbridge Biopharma?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Strongbridge Biopharma in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Strongbridge Biopharma.
Has Strongbridge Biopharma been receiving favorable news coverage?
Media stories about SBBP stock have trended negative this week, InfoTrie reports. The research firm scores the sentiment of media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Strongbridge Biopharma earned a coverage optimism score of -2.3 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 2.0 out of 10, meaning that recent media coverage is very unlikely to have an impact on the company's share price in the immediate future.
Are investors shorting Strongbridge Biopharma?
Strongbridge Biopharma saw a decline in short interest in the month of March. As of March 15th, there was short interest totalling 417,713 shares, a decline of 40.1% from the February 28th total of 697,310 shares. Based on an average daily volume of 170,555 shares, the short-interest ratio is currently 2.4 days. Approximately 1.2% of the shares of the stock are sold short. View Strongbridge Biopharma's Current Options Chain.
Who are some of Strongbridge Biopharma's key competitors?
Some companies that are related to Strongbridge Biopharma include Radius Health (RDUS), Amphastar Pharmaceuticals (AMPH), Dicerna Pharmaceuticals (DRNA), Omeros (OMER), Rhythm Pharmaceuticals (RYTM), Deciphera Pharmaceuticals (DCPH), Kiniksa Pharmaceuticals (KNSA), Y-mAbs Therapeutics (YMAB), Vanda Pharmaceuticals (VNDA), Alder Biopharmaceuticals (ALDR), Wave Life Sciences (WVE), Ra Pharmaceuticals (RARX), Eidos Therapeutics (EIDX), Homology Medicines (FIXX) and Advanz Pharma (CXRXF).
What other stocks do shareholders of Strongbridge Biopharma own?
Who are Strongbridge Biopharma's key executives?
Strongbridge Biopharma's management team includes the folowing people:
- Mr. Matthew Pauls, CEO, Pres & Director (Age 48)
- Mr. A. Brian Davis, Chief Financial Officer (Age 52)
- Dr. Fredric Cohen, Chief Medical Officer (Age 54)
- Dr. Per Marin M.D., Ph.D., Founder and Sr. Clinical Advisor
- Mr. Peter J. Valentinsson, Sr. VP of Global Technical Operations
Who are Strongbridge Biopharma's major shareholders?
Which institutional investors are buying Strongbridge Biopharma stock?
How do I buy shares of Strongbridge Biopharma?
Shares of SBBP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Strongbridge Biopharma's stock price today?
One share of SBBP stock can currently be purchased for approximately $4.50.
How big of a company is Strongbridge Biopharma?
Strongbridge Biopharma has a market capitalization of $243.77 million and generates $18.03 million in revenue each year. The biotechnology company earns $31.85 million in net income (profit) each year or $0.31 on an earnings per share basis.
What is Strongbridge Biopharma's official website?
How can I contact Strongbridge Biopharma?
Strongbridge Biopharma's mailing address is 900 NORTHBROOK DRIVE SUITE 200, TREVOSE PA, 19053. The biotechnology company can be reached via phone at 610-254-9200 or via email at [email protected]
MarketBeat Community Rating for Strongbridge Biopharma (NASDAQ SBBP)
MarketBeat's community ratings are surveys of what our community members think about Strongbridge Biopharma and other stocks. Vote "Outperform" if you believe SBBP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SBBP will underperform the S&P 500 over the long term. You may vote once every thirty days.
